Theranostic quantum dots for crossing blood-brain barrier in vitro and providing therapy of HIV-associated encephalopathy

Frontiers in Pharmacology

Volumn 4 NOV, Issue , 2013, Pages

  Xu, Gaixia ^a   Mahajan, Supriya ^b   Roy, Indrajit ^c   Yong, Ken Tye ^d  

^a SHENZHEN UNIVERSITY   (China)

^b UNIVERSITY AT BUFFALO   (United States)

^c UNIVERSITY OF DELHI   (India)

^d NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

Author keywords

Drug delivery; HIV associated encephalopathy; In vitro blood brain barrier model; Nanomedicine; Theranostic quantum dots

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; QUANTUM DOT; SAQUINAVIR; SMALL INTERFERING RNA;

ARTICLE; BLOOD BRAIN BARRIER; BRAIN DISEASE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG SCREENING; GENE SILENCING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED ENCEPHALOPATHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; IN VIVO STUDY; NANOMEDICINE; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; TRANSCYTOSIS; UNSPECIFIED SIDE EFFECT;

EID: 84889670430     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2013.00140     Document Type: Article

References (63)

1. Abbott, N. J. (2002). Astrocyte-endothelial interactions and blood-brain barrier permeability. J. Anat. 200, 629-638. doi: 10.1046/j.1469-7580.2002.00064.x
2. Abbott, N. J., and Friedman, A. (2012). Overview and introduction: the blood-brain barrier in health and disease. Epilepsia 53, 1-6. doi: 10.1111/j.1528-1167.2012.03696.x
3. Abbott, N. J., Patabendige, A. A. K., Dolman, D. E. M., Yusof, S. R., and Begley, D. J. (2010). Structure and function of the blood-brain barrier. Neurobiol. Dis. 37, 13-25. doi: 10.1016/j.nbd.2009.07.030
4. Alexaki, A., Liu, Y. J., and Wigdahl, B. (2008). Cellular reservoirs of HIV-1 and their role in viral persistence. Curr. HIV Res. 6, 388-400. doi: 10.2174/157016208785861195
5. Ballabh, P., Braun, A., and Nedergaard, M. (2004). The blood-brain barrier: an overview: structure, regulation, and clinical implications. Neurobiol. Dis. 16, 1-13. doi: 10.1016/j.nbd.2003.12.016
6. Banks, W. A. (1999). Physiology and pathology of the blood-brain barrier: implications for microbial pathogenesis, drug delivery and neurodegenerative disorders. J. Neurovirol. 5, 538-555. doi: 10.3109/13550289909021284
7. Banks, W. A., Ercal, N., and Price, T. O. (2006). The blood-brain barrier in neuroAIDS. Curr. HIV Res. 4, 259-266. doi: 10.2174/157016206777709447
8. Berger, J. R., and Avison, M. (2004). The blood brain barrier in HIV infection. Front. Biosci. 9, 2680-2685. doi: 10.2741/1427
9. Bharali, D. J., Lucey, D. W., Jayakumar, H., Pudavar, H. E., and Prasad, P. N. (2005). Folate-receptor-mediated delivery of InP quantum dots for bioimaging using confocal and two-photon microscopy. J. Am. Chem. Soc. 127, 11364-11371. doi: 10.1021/ja051455x
10. Bonoiu, A., Mahajan, S. D., Ye, L., Kumar, R., Ding, H., Yong, K.-T., et al. (2009). MMP-9 gene silencing by a quantum dot-siRNA nanoplex delivery to maintain the integrity of the blood brain barrier. Brain Res. 1282, 142-155. doi: 10.1016/j.brainres.2009.05.047
11. Bradbury, M. W. (1993). The blood-brain barrier. Exp. Physiol. 78, 453-472.
12. Bruchez, M., Moronne, M., Gin, P., Weiss, S., and Alivisatos, A. P. (1998). Semiconductor nanocrystals as fluorescent biological labels. Science 281, 2013-2016. doi: 10.1126/science.281.5385.2013
13. Chan, W. C. W., and Nie, S. M. (1998). Quantum dot bioconjugates for ultrasensitive nonisotopic detection. Science 281, 2016-2018. doi: 10.1126/science.281.5385.2016
14. Cucullo, L., Aumayr, B., Rapp, E., and Janigro, D. (2005). Drug delivery and in vitro models of the blood-brain barrier. Curr. Opin. Drug Discov. Dev. 8, 89-99.
15. Cucullo, L., Marchi, N., Hossain, M., and Janigro, D. (2011). A dynamic in vitro BBB model for the study of immune cell trafficking into the central nervous system. J. Cereb. Blood Flow Metab. 31, 767-777. doi: 10.1038/jcbfm.2010.162
16. Cucullo, L., McAllister, M. S., Kight, K., Krizanac-Bengez, L., Marroni, M., Mayberg, M. R., et al. (2002). A new dynamic in vitro model for the multidimensional study of astrocyte-endothelial cell interactions at the blood-brain barrier. Brain Res. 951, 243-254. doi: 10.1016/S0006-8993(02)03167-0
17. Davis, S. S. (1997). Biomedical applications of nanotechnology-implications for drug targeting and gene therapy. Trends Biotechnol. 15, 217-224. doi: 10.1016/S0167-7799(97)01036-6
18. de Lange, E. C. M. (2012). The physiological characteristics and transcytosis mechanisms of the blood-brain barrier (BBB). Curr. Pharm. Biotechnol. 13, 2319-2327. doi: 10.2174/138920112803341860
19. Erickson, M. A., Dohi, K., and Banks, W. A. (2012). Neuroinflammation: a common pathway in CNS diseases as mediated at the blood-brain barrier. Neuroimmunomodulation 19, 121-130. doi: 10.1159/000330247
20. Erogbogbo, F., Yong, K.-T., Roy, I., Xu, G., Prasad, P. N., and Swihart, M. T. (2008). Biocompatible luminescent silicon quantum dots for imaging of cancer cells. ACS Nano 2, 873-878. doi: 10.1021/nn700319z
21. Fromm, M. F. (2000). P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int. J. Clin. Pharmacol. Ther. 38, 69-74. doi: 10.5414/CPP38069
22. Gao, X. H., Yang, L. L., Petros, J. A., Marshal, F. F., Simons, J. W., and Nie, S. M. (2005). In vivo molecular and cellular imaging with quantum dots. Curr. Opin. Biotechnol. 16, 63-72. doi: 10.1016/j.copbio.2004.11.003
23. Ghose, A. K., Viswanadhan, V. N., and Wendoloski, J. J. (1999). A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. J. Comb. Chem. 1, 55-68. doi: 10.1021/cc9800071
24. Hardman, R. (2006). A toxicologic review of quantum dots: toxicity depends on physicochemical and environmental factors. Environ. Health Perspect. 114, 165-172. doi: 10.1289/ehp.8284
25. Hedi, M., Matthew, M., Ellen, R. G., George, P. A., Vikram C. S., Frederic V. M., et al. (2000). Self-assembly of CdSe-ZnS quantum dot bioconjugates using an engineered recombinant protein. J. Am. Chem. Soc. 122, 12142-12150. doi: 10.1021/ja002535y
26. Hilderbrand, S. A., and Weissleder, R. (2010). Near-infrared fluorescence: application to in vivo molecular imaging. Curr. Opin. Chem. Biol. 14, 71-79. doi: 10.1016/j.cbpa.2009.09.029
27. Jain, K. K. (2012). Nanobiotechnology-based strategies for crossing the blood-brain barrier. Nanomedicine 7, 1225-1233. doi: 10.2217/nnm.12.86
28. Joo, F. (1993). The blood-brain barrier in vitro: the second decade. Neurochem. Int. 23, 499-521. doi: 10.1016/0197-0186(93)90098-P
29. Kreuter, J. (2004). Influence of the surface properties on nanoparticle-mediated transport of drugs to the brain. J. Nanosci. Nanotechnol. 4, 484-488. doi: 10.1166/jnn.2003.077
30. Kubitschko, S., Spinke, J., Bruckner, T., Pohl, S., and Oranth, N. (1997). Sensitivity enhancement of optical immunosensors with nanoparticles. Anal. Biochem. 253, 112-122. doi: 10.1006/abio.1997.2337
31. Lipinski, C. A. (2000). Drug-like properties and the causes of poor solubility and poor permeability. J. Pharmacol. Toxicol. Methods 44, 235-249. doi: 10.1016/S1056-8719(00)00107-6
32. Liu, L., Hu, R., Law, W.-C., Roy, I., Zhu, J., Ye, L., et al. (2013). Optimizing the synthesis of red- and near-infrared CuInS2 and AgInS2 semiconductor nanocrystals for bioimaging. Analyst 138, 6144-6153. doi: 10.1039/c3an01030a
33. Lucey, D. W., MacRae, D. J., Furis, M., Sahoo, Y., Cartwright, A. N., and Prasad, P. N. (2005). Monodispersed InP quantum dots prepared by colloidal chemistry in a noncoordinating solvent. Chem. Mater. 17, 3754-3762. doi: 10.1021/cm050110a
34. Luissint, A.-C., Artus, C., Glacial, F., Ganeshamoorthy, K., and Couraud, P.-O. (2012). Tight junctions at the blood brain barrier: physiological architecture and disease-associated dysregulation. Fluids Barriers CNS 9, 23. doi: 10.1186/2045-8118-9-23
35. Mahajan, S. D., Law, W.-C., Aalinkeel, R., Reynolds, J., Nair, B. B., Yong, K.-T., et al. (2012). Nanoparticle-mediated targeted delivery of antiretrovirals to the brain. Methods Enzymol. 509, 41-60. doi: 10.1016/B978-0-12-391858-1.00003-4
36. Mahajan, S. D., Roy, I., Xu, G., Yong, K.-T., Ding, H., Aalinkeel, R., et al. (2010). Enhancing the delivery of anti retroviral drug "Saquinavir" across the blood brain barrier using nanoparticles. Curr. HIV Res. 8, 396-404. doi: 10.2174/157016210791330356
37. Medintz, I. L., Uyeda, H. T., Goldman, E. R., and Mattoussi, H. (2005). Quantum dot bioconjugates for imaging, labelling and sensing. Nat. Mater. 4, 435-446. doi: 10.1038/nmat1390
38. Michalet, X., Pinaud, F. F., Bentolila, L. A., Tsay, J. M., Doose, S., Li, J. J., et al. (2005). Quantum dots for live cells, in vivo imaging, and diagnostics. Science 307, 538-544. doi: 10.1126/science.1104274
39. Mukhtar, M., and Pomerantz, R. J. (2000). Development of an in vitro blood-brain barrier model to study molecular neuropathogenesis and neurovirologic disorders induced by human immunodeficiency virus type 1 infection. J. Hum. Virol. 3, 324-334.
40. Naik, P., and Cucullo, L. (2012). In vitro blood-brain barrier models: current and perspective technologies. J. Pharm. Sci. 101, 1337-1354. doi: 10.1002/jps.23022
41. Pardridge, W. M. (2012). Drug transport across the blood-brain barrier. J. Cereb. Blood Flow Metab. 32, 1959-1972. doi: 10.1038/jcbfm.2012.126
42. Pardridge, W. M., and Boado, R. J. (2012). Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier. Methods Enzymol. 203(Pt B), 269-292. doi: 10.1016/B978-0-12-396962-0.00011-2
43. Persidsky, Y., Stins, M., Way, D., Witte, M. H., Weinand, M., Kim, K. S., et al. (1997). Model for monocyte migration through the blood-brain barrier during HIV-1 encephalitis. J. Immunol. 158, 3499-3510.
44. Pinaud, F., Clarke, S., Sittner, A., and Dahan, M. (2010). Probing cellular events, one quantum dot at a time. Nat. Methods 7, 275-285. doi: 10.1038/nmeth.1444
45. Prasad, P. N. (2004). Introduction to Biophotonics. New York: Wiley-Interscience. doi: 10.1002/0471465380
46. Qian, J., Yong, K.-T., Roy, I., Ohulchanskyy, T. Y., Bergey, E. J., Lee, H. H., et al. (2007). Imaging pancreatic cancer using surface-functionalized quantum dots. J. Phys. Chem. B 111, 6969-6972. doi: 10.1021/jp070620n
47. Rubin, L. L., Hall, D. E., Porter, S., Barbu, K., Cannon, C., Horner, H. C., et al. (1991). A cell culture model of the blood-brain barrier. J. Cell Biol. 115, 1725-1735. doi: 10.1083/jcb.115.6.1725
48. Santaguida, S., Janigro, D., Hossain, M., Oby, E., Rapp, E., and Cucullo, L. (2006). Side by side comparison between dynamic versus static models of blood-brain barrier in vitro: a permeability study. Brain Res. 1109, 1-13. doi: 10.1016/j.brainres.2006.06.027
49. Schinkel, A. H. (1999). P-Glycoprotein, a gatekeeper in the blood-brain barrier. Adv. Drug Deliv. Rev. 36, 179-194. doi: 10.1016/S0169-409X(98)00085-4
50. Stanness, K. A., Guatteo, E., and Janigro, D. (1996). A dynamic model of the blood-brain barrier "in vitro." Neurotoxicology 17, 481-496.
51. Stanness, K. A., Neumaier, J. F., Sexton, T. J., Grant, G. A., Emmi, A., Maris, D. O., et al. (1999). A new model of the blood-brain barrier: co-culture of neuronal, endothelial and glial cells under dynamic conditions. Neuroreport 10, 3725-3731. doi: 10.1097/00001756-199912160-00001
52. Strazza, M., Pirrone, V., Wigdahl, B., and Nonnemacher, M. R. (2011). Breaking down the barrier: the effects of HIV-1 on the blood-brain barrier. Brain Res. 1399, 96-115. doi: 10.1016/j.brainres.2011.05.015
53. Sun, H., Dai, H., Shaik, N., and Elmquist, W. F. (2003). Drug efflux transporters in the CNS. Adv. Drug Deliv. Rev. 55, 83-105. doi: 10.1016/S0169-409X(02)00172-2
54. Titus, M. A., and Gilbert, S. P. (1999). The diversity of molecular motors: an overview. Cell. Mol. Life Sci. 56, 181-183. doi: 10.1007/s000180050420
55. Uhrich, K. E., Cannizzaro, S. M., Langer, R. S., and Shakesheff, K. M. (1999). Polymeric systems for controlled drug release. Chem. Rev. 99, 3181-3198. doi: 10.1021/cr940351u
56. Uyeda, H. T., Medintz, I. L., Jaiswal, J. K., Simon, S. M., and Mattoussi, H. (2005). Synthesis of compact multidentate ligands to prepare stable hydrophilic quantum dot fluorophores. J. Am. Chem. Soc. 23, 3870-3878. doi: 10.1021/ja044031w
57. Weiss, N., Miller, F., Cazaubon, S., and Couraud, P. O. (2009). The blood-brain barrier in brain homeostasis and neurological diseases. Biochim. Biophys. Acta 1788, 842-857. doi: 10.1016/j.bbamem.2008.10.022
58. Won, H. S., Kenneth, S. S., Galen, D. S., and Yoo-Hun S. (2009). Nanotechnology, nanotoxicology, and neuroscience. Prog. Neurobiol. 87, 133-170. doi: 10.1016/j.pneurobio.2008.09.009
59. Xu, G., Yong, K.-T., Roy, I., Mahajan, S. D., Ding, H., Schwartz, S. A., et al. (2008). Bioconjugated quantum rods as targeted probes for efficient transmigration across an in vitro blood-brain barrier. Bioconjug. Chem. 19, 1179-1185. doi: 10.1021/bc700477u
60. Yong, K.-T., Ding H., Roy, I., Law, W. C., Bergey, E. J., Maitra, A., et al. (2009a). Imaging pancreatic cancer using bioconjugated InP quantum dots. ACS Nano 3, 502-510. doi: 10.1021/nn8008933
61. Yong, K.-T., Roy, I., Swihart, M. T., and Prasad, P. N. (2009b). Multifunctional nanoparticles as biocompatible targeted probes for human cancer diagnosis and therapy. J. Mater. Chem. 19, 4655-4672. doi: 10.1039/b817667c
62. Yong, K.-T., Roy, I., Hu, R., Ding, H., Cai, H., Zhu, J., et al. (2010). Synthesis of ternary CuInS2/ZnS quantum dot bioconjugates and their applications for targeted cancer bioimaging. Integr. Biol. 2, 121-129. doi: 10.1039/b916663g/
63. Yong, K.-T., Xu, G., and Roy, I. (2011). Engineering arginine cross-linked mercaptoundecanoic acid CdSe/CdS/ZnS quantum dots for two-photon imaging of live cancer cells. Chem. Commun. 47, 2901-2903. doi: 10.1039/c0cc05041e